Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRIPHON open-label extension of selexipag in pulmonary arterial hypertension
NL-OMON41513Phase 3Active, not recruiting
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of selexipag in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Started Jul 2014; status: active, not recruiting.
02
Drugs
selexipag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON41513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41513.